Gastric/cardiac: 12 None specified (PLA General Hospital and Survival rates calculated using Institute 207 of the Kaplan–Meier method; predictive Breast: 11 Objectives Aerospace Industry factors compared with log-rank Lung: 12 To examine predictors of survival in Company, Beijing, China) test; multivariate Cox’s patients undergoing MTA for liver Pancreatic: 1 proportional hazards model 2450 MHz, 10–80 W metastases Gallbladder: 2 Duration of follow-up Renal: 5 Mean 25.1 ± 11.4 months, range Ocular melanoma: 1 5–83 months Small bowel leiomyosarcoma: 2 Male/female: 44/30 Age (range): 27–81 y (no mean reported) 4 patients had only liver Abe et al () Case series N = 8 Inclusion MTA Outcomes metastases, 4 had liver Japan Level IV All breast metastases Limit of 5 lesions in each patient Microwave coagulator Treatment efficacy, side-effects, and other metastases (Microtase, OT-110M, complications Quality: moderate All female Lesions <3 cm diameter Osaka, Japan) Focus of paper was on Statistical analyses Mean age (range): Exclusion imaging rather than 2.45 GHz, 60 W 49.0 (41–69) y None undertaken Major coagulation disorders and intervention Ablation duration 60 s, hepatic failure Duration of follow-up usually 3 ablations at each Objectives Mean 25.9 months (range 1–43 point months) To evaluate the efficacy of MTA for MRI guided local control of liver metastases from breast cancer Li et al () Case series N = 18 Inclusion MTA Outcomes - China Level IV Nasopharyngeal Karnofsky performance status >80 Percutaneous MTA Survival; complications metastases Qinghai Microwave Quality: moderate Max 5 liver lesions Statistical analyses Electronic Institute, Nanjing, Male/female: 15/3 Failure of previous chemotherapy or Kaplan–Meier survival curves China) Mean age (range): ineligible for chemotherapy Duration of follow-up 14-gauge cooled-shaft 45.7 (31–61) y Local control of primary tumour by 22.4 months (range 4–52 months) antenna Single metastasis in n radiation therapy Power 50–60 W = 14, 2 metastases in Local control or absence of n = 3, 4 metastases in Cumulative ablation time extrahepatic metastases
Gastric/cardiac: 12 Breast: 11 Lung: 12 Pancreatic: 1 Gallbladder: 2 Renal: 5 Ocular melanoma: 1 Small bowel leiomyosarcoma: 2 Male/female: 44/30 Age (range): 27–81 y (no mean reported) None specified Objectives To examine predictors of survival in patients undergoing MTA for liver metastases (PLA General Hospital and Institute 207 of the Aerospace Industry Company, Beijing, China) 2450 MHz, 10–80 W Survival rates calculated using Kaplan–Meier method; predictive factors compared with log-rank test; multivariate Cox’s proportional hazards model Duration of follow-up Mean 25.1 ± 11.4 months, range 5–83 months Abe et al () Japan Case series Level IV Quality: moderate N = 8 All breast metastases All female Mean age (range): 49.0 (41–69) y Inclusion Limit of 5 lesions in each patient Lesions <3 cm diameter Exclusion Major coagulation disorders and hepatic failure Objectives To evaluate the efficacy of MTA for local control of liver metastases from breast cancer MTA Microwave coagulator (Microtase, OT-110M, Osaka, Japan) 2.45 GHz, 60 W Ablation duration 60 s, usually 3 ablations at each point MRI guided Outcomes Treatment efficacy, side-effects, complications Statistical analyses None undertaken Duration of follow-up Mean 25.9 months (range 1–43 months) 4 patients had only liver metastases, 4 had liver and other metastases Focus of paper was on imaging rather than intervention Li et al () China Case series Level IV Quality: moderate N = 18 Nasopharyngeal metastases Male/female: 15/3 Mean age (range): 45.7 (31–61) y Single metastasis in n = 14, 2 metastases in n = 3, 4 metastases in Inclusion Karnofsky performance status >80 Max 5 liver lesions Failure of previous chemotherapy or ineligible for chemotherapy Local control of primary tumour by radiation therapy Local control or absence of extrahepatic metastases MTA Percutaneous MTA Qinghai Microwave Electronic Institute, Nanjing, China) 14-gauge cooled-shaft antenna Power 50–60 W Cumulative ablation time Outcomes Survival; complications Statistical analyses Kaplan–Meier survival curves Duration of follow-up 22.4 months (range 4–52 months) -
1402-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx